News
- Author:
- Mary Jo M. Dales
Publish date: September 1, 2018
Analysis of the sequence context surrounding chromoplexy breaks may provide clues and potentially point to a therapeutic vulnerability that could b...
News
- Author:
- Mary Jo M. Dales
Publish date: August 23, 2018
To address concerns regarding the voluntary recall of some valsartan products, affected drugmakers and the FDA have issued advisories for recognizi...
News
- Author:
- Mary Jo M. Dales
Publish date: August 10, 2018
The first vaginal ring contraceptive that can be used for 1 year has been approved by the Food and Drug Administration.
News
- Author:
- Mary Jo M. Dales
Publish date: July 20, 2018
Nivestym (filgrastim-aafi), a biosimilar to Neupogen (filgrastim) was approved July 20 by the FDA.
News
- Author:
- Mary Jo M. Dales
Publish date: July 20, 2018
According to the FDA, Bayer stated its decision to halt sales and distribution of the device was because of commercial reasons.
News
- Author:
- Mary Jo M. Dales
Publish date: July 19, 2018
One proposed step is to release a series of videos that explain key concepts about biosimilar and interchangeable products.
News
- Author:
- Mary Jo M. Dales
Publish date: July 9, 2018
Pazopanib elicited clinically meaningful responses in adults with progressive desmoid tumors according to RECIST 1.1 criteria, based o...
News
- Author:
- Mary Jo M. Dales
Publish date: July 2, 2018
Anlotinib was confirmed to be safe and effective for soft tissue sarcoma patients who have progressed after first-line chemotherapy, b...
News
- Author:
- Mary Jo M. Dales
Publish date: June 29, 2018
Regorafenib appears to be active in patients with metastatic osteosarcomas, based on results from REGOBONE a non-comparative phase 2, ...
News
- Author:
- Mary Jo M. Dales
Publish date: June 28, 2018
Sorafenib was well tolerated with significantly improved progression-free survival in select patients with desmoid tumors, reported Mr...
News
- Author:
- Mary Jo M. Dales
Publish date: June 28, 2018
Regorafenib fell short of improving progression-free survival in patients with treatment-refractory liposarcomas, Richard Reidel, MD, ...
News
- Author:
- Mary Jo M. Dales
Publish date: June 27, 2018
Pazopanib can be considered as a first line alternative treatment to doxorubicin in patients over age 60 with advanced, inoperable sof...
News
- Author:
- Mary Jo M. Dales
Publish date: June 27, 2018
Pexidartinib significantly improved overall response rates and functioning in patients with advanced tenosynovial giant cell tumors (T...
News
- Author:
- Mary Jo M. Dales
Publish date: May 22, 2018
Avatrombopag (Doptelet) is the first drug approved for thrombocytopenia in adults who have chronic liver disease and are undergoing a procedure.
News
- Author:
- Mary Jo M. Dales
Publish date: May 14, 2018
